


Product Name : Darovasertib
Cat. No. : PC-38356
CAS No. : 1874276-76-2
Molecular Formula : C₂₂H₂₃F₃N₈O
Molecular Weight : 472.47
Target : PKC
Solubility : 10 mM in DMSO



Biological Activity

Darovasertib (NVP-LXS196, LXS 196, IDE 196) is a potent, selective, oral pan- protein kinase C (**PKC**) inhibitor with IC₅₀ of 3 nM and 0.6 nM for PKC α and PKC θ , respectively.

Darovasertib (NVP-LXS196, LXS 196, IDE 196) demonstrates high potency toward classical PKC isoforms (IC₅₀s=2.9-1.9 nM). Darovasertib (NVP-LXS196, LXS 196, IDE 196) shows comparable cellular potency (IC₅₀=170 nM) versus AEB071 in the 92.1 cellular proliferation assays.

Darovasertib (NVP-LXS196, LXS 196, IDE 196) demonstrates antitumor efficacy and tolerability in the 92.1 tumor xenograft model in mice.

References

Ellen Kapiteijn, et al. **Cancer Res** (2019) 79 (13_Supplement): CT068.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com